Vaxart (NASDAQ: VXRT) SVP and General Counsel granted shares and options

Rhea-AI Filing Summary

Vaxart, Inc. SVP and General Counsel Edward B. Berg received new equity awards as part of his compensation. On March 16, 2026, he was granted 115,000 shares of common stock upon vesting of restricted stock units, with 25% of the units vesting on each anniversary of the March 16, 2026 vesting commencement date until fully vested after four years.

He was also granted a stock option for 225,000 shares of common stock at an exercise price of $0.6795 per share, expiring on March 16, 2036. The option vests 25% on March 16, 2027 and then in 36 equal monthly installments so it is fully vested by March 16, 2030. Following these grants, Berg directly holds 799,858 common shares.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Berg Edward B

Role SVP, General Counsel

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	225,000	$0.00	--
Grant/Award	Common Stock	115,000	$0.00	--

Holdings After Transaction: Stock Option (right to buy) — 225,000 shares (Direct); Common Stock — 799,858 shares (Direct)

Footnotes (1)

1. Grant of shares upon vesting of restricted stock units. 25% of the shares underlying the award shall vest on each anniversary of the vesting commencement date of March 16, 2026, so that the restricted stock units would be fully vested on the fourth anniversary of the vesting commencement date. The shares subject to this stock option shall vest as to 25% of the shares underlying the grant on March 16, 2027, the first anniversary of the date that vesting commenced, and thereafter in 36 equal monthly installments such that the stock option shall be fully vested on March 16, 2030.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Berg Edward B

(Last) (First) (Middle)

C/O VAXART, INC.

170 HARBOR WAY, SUITE 300

(Street)

SOUTH SAN FRANCISCO CALIFORNIA 94080

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Vaxart, Inc. [ VXRT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP, General Counsel

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/16/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/16/2026		A		115,000(1)	A	$0	799,858	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$0.6795	03/16/2026		A		225,000		(2)	03/16/2036	Common Stock	225,000	$0	225,000	D

Explanation of Responses:

1. Grant of shares upon vesting of restricted stock units. 25% of the shares underlying the award shall vest on each anniversary of the vesting commencement date of March 16, 2026, so that the restricted stock units would be fully vested on the fourth anniversary of the vesting commencement date.

2. The shares subject to this stock option shall vest as to 25% of the shares underlying the grant on March 16, 2027, the first anniversary of the date that vesting commenced, and thereafter in 36 equal monthly installments such that the stock option shall be fully vested on March 16, 2030.

	/s/ Edward B. Berg	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transactions did Vaxart (VXRT) report for Edward B. Berg?

Vaxart reported that SVP and General Counsel Edward B. Berg received equity compensation grants. He was awarded restricted stock units for 115,000 common shares and a stock option covering 225,000 shares, both granted on March 16, 2026 with multi-year vesting schedules.

How many restricted stock units and options did VXRT grant to Edward B. Berg?

Edward B. Berg received 115,000 restricted stock units and a stock option for 225,000 Vaxart common shares. These grants are compensation awards, not open-market purchases, and they will vest over several years subject to the specific schedules outlined in the filing footnotes.

What are the vesting terms of Edward B. Berg’s VXRT restricted stock units?

The 115,000 restricted stock units begin vesting from March 16, 2026. Twenty-five percent of the underlying shares vest on each anniversary of that vesting commencement date, so the units become fully vested on the fourth anniversary, assuming continued service through each vesting date.

How does Edward B. Berg’s VXRT stock option vest and when does it expire?

The 225,000-share stock option vests 25% on March 16, 2027, the first anniversary of vesting commencement. The remaining shares vest in 36 equal monthly installments, fully vesting by March 16, 2030. The option carries an exercise price of $0.6795 and expires March 16, 2036.

Did Edward B. Berg buy or sell VXRT shares in the open market?

No open-market buying or selling was reported. The Form 4 shows compensation-related acquisitions: restricted stock units and a stock option grant with a transaction code A, indicating awards rather than discretionary market trades, so there is no reported purchase or sale price per share.

How many Vaxart shares does Edward B. Berg hold after these grants?

After the March 16, 2026 grants, Edward B. Berg directly holds 799,858 shares of Vaxart common stock. He also holds a newly granted stock option covering 225,000 underlying shares, which will become exercisable over time as the specified vesting schedule is satisfied.